

INVITATION TO CCIT SEMINAR

Monday May 30th, 2016, at 14.00

SPEAKER

Isabel Poschke, M.Sc., PhD.

Division of Molecular Oncology of Gastrointestinal Tumors,
German Cancer Research Center, Heidelberg, Germany

Title

**"Identification of a tumor-reactive T-cell repertoire in
the immune infiltrate of resectable pancreatic ductal
adenocarcinoma"**

Place

Meeting room 53 K2D
Herlev University Hospital
Herlev Ringvej 75
2730 Herlev

We welcome you all to this exciting seminar!

Per thor Straten
Director

How to get there; you can enter the hospital at the main entrance in which case you can ask for directions at the reception. Alternatively, The auditorium is on 3rd floor in the square K2. Use entrance 57, 62 or 106. Take the elevator (between J and K) to the third floor. When exiting the elevator turn left around the K square. Enter between K and L, go through the glass door, the auditorium is on your right.

Abstract enclosed

CENTER FOR CANCER IMMUNOTERAPI



Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of resectable pancreatic ductal adenocarcinoma

Isabel Poschke - Div. Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany

Adoptive transfer of tumor-infiltrating T cells has shown striking efficacy in patients with metastatic melanoma, even in late stage patients, and therefore needs to be explored as a therapeutic option for other highly metastatic cancers.

Pancreatic ductal adenocarcinoma (PDA), a disease with poor prognosis and a high recurrence rate after resection of the primary tumor, is still widely regarded as a poorly immunogenic tumor. We are the first to provide evidence - by means of TCR deep sequencing - for a tumor-enriched T-cell repertoire in this cancer type, resulting from in situ clonal expansion. Furthermore, we obtained proof of concept for the successful isolation, in vitro expansion and tumor-reactivity of tumor-infiltrating lymphocytes (TILs) from PDA patients. Our findings indicate that T-cell-based therapy represents a promising path for countering tumor recurrence in patients with resectable PDA, and thereby has the potential to significantly improve the management of this disease.

In parallel, we are making use of TCR repertoire analysis to understand the general requirement for a successful anti-tumor response by interrogating the generation of the TIL repertoire, its maintenance during in vitro expansion for therapeutic purposes and changes of TIL composition after immune-checkpoint inhibitor treatment.



Enter at entrance 57, 62 or 106. Take the elevator (between J and K) to the third floor.